

## COVID-19 Monoclonal Antibody Eligibility Checklist

The Maine Department of Health & Human Services (ME DHHS) has developed this eligibility checklist as a resource for clinicians to use to identify individuals appropriate for COVID-19 monoclonal antibody (mAb) treatment. There are currently three products authorized under Emergency Use Authorization (EUA): [Bamlanivimab and etesevimab](#), [REGEN-COV](#), and [sotrovimab](#).<sup>1</sup> COVID-19 monoclonal antibodies are currently indicated for two purposes:

- (1) Treatment for individuals with active COVID-19 who are at high-risk for progression to severe COVID-19, *OR*
- (2) Post-exposure prophylaxis for close contacts in congregate settings who are at high-risk for progression to severe COVID-19

<b>Determine Eligibility for Monoclonal Antibody Treatment</b>	
<b>(1) Treatment for Active COVID-19 Infection</b>	<b>(2) Post-Exposure Prophylaxis of Close Contacts in Congregate Settings</b>
1. Is the patient 12 years of age or older weighing at least 88 pounds? If <b>NO</b> , <b>STOP</b> ; If <b>YES</b> , proceed to number 2.	1. Is the patient 12 years of age or older weighing at least 88 pounds? If <b>NO</b> , <b>STOP</b> ; If <b>YES</b> , proceed to number 2.
2. Does the patient have a positive COVID-19 PCR or antigen test result? If <b>NO</b> , <b>STOP</b> ; If <b>YES</b> , proceed to number 3.	2. Has the patient had a high-risk exposure as defined by US CDC Quarantine and Isolation guidance <sup>2</sup> ? If <b>NO</b> , <b>Proceed to Number 3</b> ; If <b>YES</b> , proceed to number 4.
3. Does the COVID-19 positive patient have mild to moderate COVID-19 symptoms such as fever, cough, shortness of breath, loss of taste/smell, fatigue, nausea, vomiting, diarrhea, throat pain, congestion, myalgia, or headache? If <b>NO</b> , <b>STOP</b> ; <b>YES</b> , proceed to number 4.	3. Is the patient at high risk of exposure to an individual infected with COVID-19 in the same institutional setting? If <b>NO</b> , <b>STOP</b> ; <b>YES</b> , proceed to number 4.
4. Has it been less than 10 days since symptom onset and positive COVID-19 test result? If <b>NO</b> , <b>STOP</b> ; <b>YES</b> , proceed to number 5.	4. If exposure occurred within the past 96 hours, patient meets eligibility criteria; proceed with administration or referral.  Patients who meet eligibility criteria can be offered mAb treatment within the facility (if mAb treatment available) or referred to a local Maine mAb infusion provider. <sup>5</sup>
5. Is the COVID-19 positive patient at high risk <sup>4</sup> for progression to severe COVID-19, including hospitalization or death? If <b>NO</b> , <b>STOP</b> ; <b>YES</b> , proceed to number 6.	
6. If any of the following apply, <b>STOP</b> ; the patient is not eligible for treatment. Otherwise, proceed to number 7. <ul style="list-style-type: none"> <li>• Patient hospitalized for COVID-19</li> <li>• Patient requires oxygen therapy due to COVID-19</li> <li>• Patient requires require an increase in baseline oxygen flow rate due to COVID-19</li> <li>• Patient is in imminent need of hospitalization for COVID-19</li> </ul>	
7. Patient meets eligibility criteria; proceed with administration or referral. Patients who meet eligibility criteria can be offered mAb treatment within the facility (if mAb treatment available) or referred to a local Maine mAb infusion provider. <sup>5</sup>	

<sup>1</sup> Sotrovimab is not authorized for post-exposure prophylactic administration.

<sup>2</sup> Close contact with an infected individual is defined as: being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). See US CDC website for additional details: <https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html>

<sup>3</sup> Individuals are considered to be fully vaccinated 2 weeks after their second vaccine dose in a 2-dose series (such as the Pfizer or Moderna vaccines), or 2 weeks after a single-dose vaccine (such as the Johnson & Johnson/ Janssen vaccine). See this website for more details: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fullyvaccinated.html#vaccinated>.

<sup>4</sup> For further information as what qualifies an individual as high risk please see slide 39 of the Monoclonal Antibody Clinical Implementation Guide available at: <https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Documents/USG-COVID19-Tx-Playbook.pdf>

<sup>5</sup> [List of Maine mAb providers](#) available on Maine CDC website